| Literature DB >> 27521874 |
Elizabeth M Everson1, Grant D Trobridge2.
Abstract
Hematopoietic stem cell (HSC) gene therapy using retroviral vectors is a powerful and promising approach to permanently correct many hematopoietic disorders. Increasing the transduction of quiescent HSCs and reducing genotoxicity are major challenges in the field. Retroviral vectors, including lentiviral and foamy vectors, have been extensively modified resulting in improved safety and efficacy. This review will focus on recent advances to improve vector entry, transduction efficiency, control of transgene expression and approaches to improve safety by modifying the retroviral integration profile. Copyright ÂEntities:
Mesh:
Year: 2016 PMID: 27521874 PMCID: PMC5138074 DOI: 10.1016/j.coviro.2016.07.010
Source DB: PubMed Journal: Curr Opin Virol ISSN: 1879-6257 Impact factor: 7.090